Transplacental passage of a human relaxin administered to rhesus monkeys

Authors:
  • DHD. E. Hill
    D. E. Hill
  • JBJ. R. Bailey
    J. R. Bailey
  • JAJ. H. Anderson
    J. H. Anderson
  • WSW. Slikker
    W. Slikker

Abstract
A synthetic version of the human relaxin encoded by the human gene 2 (hRlx-2) was administered to pregnant rhesus monkeys (Macaca mulatta) on gestational days 141–158. Monkeys (three per group) received doses of 100 μg/kg or 2000 μg/kg as a continuous i.v. infusion over 2 h into a radial vein. One monkey in the low-dose group received, along with the unlabelled hRlx-2, 25·5 μCi/kg of the test material internally labelled with [35S]cysteine. Immunoreactive hRlx-2, as measured by enzyme-linked immunosorbent assay, appeared in all fetuses within 30 min (the first sampling time) of beginning the infusions. Peak fetal plasma levels of hRlx-2 were only 0·8–1·5% of the maternal values. Only 8–15% of the fetal serum radioactivity was hRlx-2. Radioactivity from maternal urine pooled over the 4-h experiment did not elute at the volume corresponding to hRlx-2, but near the column volume. Journal of Endocrinology (1991) 130, 339–345